Injective (INJ) is currently priced at $3.05, reflecting a modest 24-hour change of 1.40%. The asset's daily trading range has been tight, with a high of $3.07 and a low of $2.96, indicating limited volatility and a consolidating market phase.

The trading volume stands at approximately 35.9 million, contributing to a volume-to-market cap ratio of 11.76%. This suggests a healthy trading activity relative to its market capitalization, indicating investor interest but not excessive speculative trading at this moment.

Analyzing the hourly moving averages reveals a bullish trend, with the 55 SMA at $2.98 showing a 2.40% increase and the 144 SMA at $2.92 demonstrating a notable 4.52% rise. The positive trends in the short-term moving averages suggest a potential upward momentum as prices consistently stay above these averages.

The 1-hour RSI is at 60, indicating that INJ is approaching overbought territory but still has room for upward movement. In contrast, the 7-day RSI at 54 suggests neutral market conditions, while the 14-day RSI shows a decline, indicating some selling pressure over the longer term.

In terms of price changes, INJ has seen a slight increase of 0.47% over the past week, while a 4.48% decline over the last two weeks indicates volatility and potential profit-taking. However, a positive 30-day price change of 0.42% reflects a recovery phase after previous declines, suggesting a potential stabilization in price.

Considering the all-time high of $52.62 reached on March 14, 2024, there remains significant room for growth despite the current price. The recent price behavior combined with bullish short-term indicators suggests that INJ may be poised for a potential upward breakout.

Based on the analysis, a Buy rating is warranted for Injective (INJ) at its current price of $3.05. The technical indicators are showing bullish momentum in the short term, alongside healthy trading volumes, suggesting that investors may capitalize on further upward movement.